Nathan Hochman set to take office as L.A. County D.A.SAXTON: Countdown is on for MLB Speedway Classic
TEANECK, N.J. , Nov. 22, 2024 /PRNewswire/ -- GC Biopharma USA , the commercial operations and distribution company of GC Biopharma, has announced the appointment of industry veteran, Sean Zam , to its senior leadership team as Head of Sales and Marketing. He comes to GC Biopharma USA with a wealth of experience in the pharmaceutical industry, including extensive experience in plasma therapeutics. Sean has a proven track record of growing business and building lasting partnerships for companies such as Grifols, AstraZeneca, and Pfizer. Lisa Betts , Chief Operating Officer at GC Biopharma USA , says the following about Sean: "He's everything we'd hoped to find in a sales and marketing leader. He's authentic, earnest, experienced, and passionate about the IG industry. His core values align perfectly with the unique leadership team we are building." Sean shares his excitement: "When I joined the GC Biopharma USA leadership team, I was inspired by how differently they approach the business. It's not just about business; it's about relationships and the communities they serve. It was something I knew I wanted to be a part of." He adds: "I'm always struck by the strength and resourcefulness of patients who take the initiative to find answers, especially those living with rare diseases. It propels me to push harder. That's partly why I joined this growing team. It's a great opportunity to have a real impact." Sean Zam's appointment further contributes to GC's vision of establishing excellence within its US-based operations. About GC Biopharma GC Biopharma USA , headquartered in Teaneck, NJ , established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on the expertise of our parent company GC Biopharma, a leading biopharmaceutical company delivering plasma therapies and vaccines worldwide for more than 50 years. With GC Biopharma USA , GC Biopharma will further extend its footprint, bringing its expertise and legacy to the US. This press release may contain forward-looking statements that express the current beliefs and expectations of the management at GC Biopharma and GC Biopharma USA . Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule. ©2024 GC Biopharma USA , Inc. All rights reserved. All trademarks are the property of their respective owners. ALY-C-0074 11/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/sean-zam-named-head-of-sales-and-marketing-at-gc-biopharma-usa-302314539.html SOURCE GC Biopharma USA Inc.
Is Enron back? If it's a joke, some former employees aren't laughing
Topa, Stewart, McKenzie, Sulser reach deals ahead of tender deadlineSANTA CLARA, Calif. (AP) — Getting blown out at Green Bay following another squandered late lead the previous week against Seattle has quickly turned the San Francisco 49ers from a Super Bowl contender into a team just fighting to get back to the playoffs. If San Francisco doesn't get healthy and eliminate the errors that led to Sunday's 38-10 loss to the Packers, the focus will turn from playoff permutations to what offseason changes are necessary. “I think everyone understands completely outside and inside what the situation is,” coach Kyle Shanahan said Monday. “That’s why the Seattle game was so tough of a loss and that’s why last night was even worse. We know what we got ahead of us. We know exactly what the playoff situation is. That is what it is. But really, all that matters is this week when you do need to go on a run and put a lot of wins to even think of that.” The task doesn't get any easier as the Niners (5-6) get set to play at Buffalo on Sunday night. The 49ers are hoping to get injured stars Brock Purdy , Nick Bosa and Trent Williams back for that game, but their presence alone won't fix everything that went wrong on Sunday . The defense got repeatedly gashed early and put San Francisco in a 17-0 hole before the offense even generated a first down. The running game never got going as Christian McCaffrey has looked nothing like the 2023 Offensive Player of the Year in his three games back from Achilles tendinitis. And whenever the Niners appeared to do something right, a penalty came back to haunt them. It added up to the most lopsided loss for San Francisco since the 2018 season, before Shanahan had turned the Niners into perennial contenders. “It’s probably one of the worst ones I’ve been a part of,” linebacker Fred Warner said. “It is embarrassing. You’ve got to take it on the chin, take it like a man and move on.” Despite the doom and gloom, the 49ers are only one game behind Seattle and Arizona in the NFC West standings with six games to go. But San Francisco already has three division losses and a difficult schedule featuring games against the Bills this week and Detroit in Week 17. “My optimism is not broken by any means,” tight end George Kittle said. “We still have a lot of very talented players. We will get some guys back and I still have full trust in the coaching staff to put our guys in position to make plays. I have no worry about that. But definitely an uphill grind. We'll see what we’re made of, which I’m looking forward to.” Red-zone passes to Kittle. Backup QB Brandon Allen connected on a 3-yard TD pass to Kittle late in the second quarter for San Francisco's only TD. Kittle leads the NFL with eight touchdown catches in the red zone, which is tied with Vernon Davis (2013) for the most in a season for a Niners player since 2000. Kittle was the only consistent part of the San Francisco offense with six catches for 82 yards. Avoiding penalties. San Francisco had nine penalties for 77 yards and they were costly and sloppy. The Niners had 12 men on the field on defense on back-to-back plays, three false starts, a pass interference in the end zone and three penalties on special teams, including a holding on Eric Saubert that negated an 87-yard kickoff return by Deebo Samuel to open the second half. Rookie Dominick Puni had three penalties after being penalized just once in the first 10 games. DE Leonard Floyd. There were few positive performances on defense, but Floyd had both of the team's sacks. Run defense. San Francisco allowed 169 yards rushing, including 87 in the first quarter for the team's second-worst performance in the opening quarter since 1991. The Niners missed 19 tackles, according to Pro Football Focus, as Josh Jacobs gained 83 of his 106 yards rushing after contact. Purdy took part in a light throwing session without pain on Monday and Shanahan is hopeful he can return to practice Wednesday after missing the Green Bay game with a shoulder injury. ... Bosa (hip, oblique) and Williams (ankle) also could return this week after sitting out Sunday. ... LG Aaron Banks, DT Jordan Elliott and WR Jacob Cowing all in the concussion protocol. ... RG Dominick Puni (shoulder) and CB Deommodore Lenoir (knee) underwent MRIs on Monday and the team is waiting for results. ... CB Renardo Green (neck) and LB Demetrius Flannigan-Fowles (knee) are day to day. 11 — The Niners generated only 11 first downs, tied for the fewest in any game in eight seasons under Shanahan. They also had 11 in the 2022 NFC title game loss at Philadelphia when Purdy hurt his elbow and in Week 2 against Seattle in Shanahan's first season in 2017. The 49ers visit Buffalo on Sunday night. AP NFL: https://apnews.com/hub/NFL
TORONTO and DALLAS , Dec. 3, 2024 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, wishes to notify shareholders that in case of disruption due to the ongoing Canada Post strike, the Company's meeting materials (the "Meeting Materials") for the Company's upcoming annual general meeting to be held on December 12, 2024 at 1:00 p.m. (Toronto Time) (the "Meeting"), may be viewed on the Company's SEDAR+ profile at www.sedarplus.ca and are also available electronically on the Company's website at www.perimetermed.com . The Company has delivered the completed Meeting Materials to the appropriate parties for mailing to registered and unregistered shareholders prior to the Meeting. However, due to the postal strike, it is possible that the Meeting Materials will not be delivered to shareholders prior to the Meeting. Shareholders will still be able to vote their shares either directly or by proxy, or indirectly via their intermediary. Registered and beneficial shareholders who have not received their Meeting Materials, including the proxy, can direct requests for copies of the Meeting Materials to Stephen Kilmer , Investor Relations, at the contact details below. The Company will provide copies of the Meeting Materials by email to each shareholder who requests them while the strike is ongoing, at no charge. If you are a registered shareholder, please contact Computershare Investor Services Inc. at 1-800-564-6253 (toll free within North America ) or 1-514-982-7555 to obtain your proxy form control number to cast your vote for the upcoming Meeting. If you hold shares through an intermediary such as a brokerage firm, please contact your intermediary directly for a copy of the proxy form and instructions for voting. The Company's annual financial statements and related management discussion and analysis, as well as interim financial statements and related management discussion and analysis are available on the Company's SEDAR+ profile and the Company's website as noted above. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas , Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas . The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States . Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures . Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the timing of the annual meeting, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023 , which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca , and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. SOURCE Perimeter Medical Imaging AI Inc.Illinois quick hits: $820 million granted for sustainable aviation fuel; new specialty license plates next year
Animation Guild Reaches Tentative Deal With Studios After Bargaining Over AI Guardrails and More